NCT05852262View on ClinicalTrials.gov

High-dose Cephalexin for Cellulitis (HI-DOCC)

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

446

Participants

Timeline

Start Date

August 30, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

August 1, 2026

Conditions
Cellulitis
Interventions
DRUG

Cephalexin

1000 mg PO QID for 7 days

DRUG

Cephalexin

500 mg PO QID plus oral placebo for 7 days

Trial Locations (10)

Unknown

South Health Campus, Calgary

Queen Elisabeth II Health Sciences Centre, Halifax

Kingston Health Sciences Centre, Kingston

London Health Sciences Centre, London

Thunder Bay Health Sciences Centre, Thunder Bay

Sinai Health System, Toronto

Hôpital du Sacré-Cœur de Montréal, Montreal

Enfant-Jésus Hospital, Québec

P3E 2H2

Health Sciences North, Greater Sudbury

K1Y 4E9

The Ottawa Hospital, Ottawa

Sponsors
All Listed Sponsors
collaborator

Network of Canadian Emergency Researchers (NCER)

UNKNOWN

collaborator

The Ottawa Hospital Academic Medical Association

OTHER

lead

Ottawa Hospital Research Institute

OTHER